Barclays PLC Buys 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Barclays PLC boosted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 101,257 shares of the company's stock after buying an additional 10,737 shares during the quarter. Barclays PLC owned 0.13% of CG Oncology worth $2,905,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. NEOS Investment Management LLC grew its position in CG Oncology by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after purchasing an additional 817 shares during the period. Rhumbline Advisers grew its holdings in shares of CG Oncology by 2.2% in the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock worth $1,979,000 after acquiring an additional 1,458 shares during the period. New York State Common Retirement Fund grew its holdings in shares of CG Oncology by 16.7% in the fourth quarter. New York State Common Retirement Fund now owns 13,996 shares of the company's stock worth $401,000 after acquiring an additional 2,000 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CG Oncology during the fourth quarter valued at $68,000. Finally, Legal & General Group Plc lifted its holdings in CG Oncology by 10.6% in the fourth quarter. Legal & General Group Plc now owns 29,262 shares of the company's stock valued at $839,000 after acquiring an additional 2,793 shares during the period. Institutional investors own 26.56% of the company's stock.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

CG Oncology Trading Down 2.1 %

Shares of NASDAQ:CGON traded down $0.62 during mid-day trading on Monday, reaching $28.43. The stock had a trading volume of 124,305 shares, compared to its average volume of 779,175. The business's 50 day moving average price is $23.68 and its 200 day moving average price is $28.90. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $40.47. The company has a market cap of $2.17 billion, a P/E ratio of -20.02 and a beta of 1.08.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The firm had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.11 million. Analysts predict that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on CGON. TD Cowen initiated coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating on the stock. Royal Bank of Canada raised their target price on CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a report on Tuesday, April 29th. Scotiabank began coverage on CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research report on Monday, April 28th. Finally, JPMorgan Chase & Co. started coverage on shares of CG Oncology in a research report on Friday. They set an "overweight" rating and a $41.00 price objective on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $57.70.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.